Germ-line genetic variation of TP53 in osteosarcoma

Pediatric Blood and Cancer

Volumn 49, Issue 1, 2007, Pages 28-33

  Savage, Sharon A ^a,d   Burdett, Laura ^b   Troisi, Rebecca ^a   Douglass, Chester ^c   Hoover, Robert N ^a   Chanock, Stephen J ^a,d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b SAIC FREDERICK INC   (United States)

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Genetic variation; Osteosarcoma; Single nucleotide polymorphism; TP53

Indexed keywords

ARGININE; PROLINE;

ADOLESCENT; AGED; ARTICLE; CELL GROWTH; CHILD; FAMILIAL CANCER; GENE; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; OSTEOSARCOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TP53 GENE;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53; VARIATION (GENETICS);

EID: 34249826649     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21077     Document Type: Article

References (43)

1. Parkin DM, Stiller CA, Draper GJ, et al. The international incidence of childhood cancer. Int J Cancer 1988;42:511-520.
2. Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al., eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. National Cancer Institute. SEER Program; 1999, pp 99-110.
3. Herzog CE. Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol 2005;27:215-218.
4. Wittig JC, Bickels J, Priebat D, et al. Osteosarcoma: A multidisciplinary approach to diagnosis and treatment. Am Fam Physician 2002;65:1123-1132.
5. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003;21:313-320.
6. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop 2002; 40-52.
7. Hopper JL. Genetic epidemiology of female breast cancer. Semin Cancer Biol 2001:11:367-374.
8. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-856.
9. Erichsen HC, Chanock SJ. SNPs in cancer research and treatment. Br J Cancer 2004;90:747-751.
10. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516-1517.
11. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001;27:234-236.
12. Savage SA, Chanock SJ. Genetic association studies in cancer: Good, bad or no longer ugly? Hum Genomics 2006;2:415-421.
13. Chanock S. Candidate genes and single nucleotide polymorphisms (SNPs) in the study of human disease. Dis Markers 2001;17:89-98.
14. Angele S, Falconer A, Foster CS, et al. ATM protein overexpression in prostate tumors: Possible role in telomere maintenance. Am J Clin Pathol 2004;121:231-236.
15. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: Past successes for mendelian disease, future approaches for complex disease. Nat Genet 2003;33:228-237.
16. Drumm ML, Konstan MW, Schluchter MD, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005:353:1443-1453.
17. Foster CB, Lehrnbecher T, Mol F, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest 1998;102:2146-2155.
18. Patio-Garcia A, Sotillo-Pieiro E, Modesto C, et al. Analysis of the human tumour necrosis factor-alpha (TNFalpha) gene promoter polymorphisms in children with bone cancer. J Med Genet 2000;37:789-792.
19. Ruza E, Sotillo E, Sierrasesumaga L, et al. Analysis of polymorphisms of the vitamin D receptor, estrogen receptor, and collagen Ialpha1 genes and their relationship with height in children with bone cancer. J Pediatr Hematol Oncol 2003;25:780-786.
20. Sengupta S, Harris CC. p53: Traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005:6:44-55.
21. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-799.
22. Ahrendt SA, Hu Y, Buta M, et al. p53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study. J Natl Cancer Inst 2003;95:961-970.
23. Leroy K, Haioun C, Lepage E, et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 2002:13:1108-1115.
24. Berns EM, Foekens JA, Vossen R., et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000;60:2155-2162.
25. Wunder JS, Gokgoz N, Parkes R, et al. TP53 mutations and outcome in osteosarcoma: A prospective, multicenter study. J Clin Oncol 2005:23:1483-1490.
26. Pakos EE, Kyzas PA, Ioannidis JP. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: A meta-analysis. Clin Cancer Res 2004;10:6208-6214.
27. Packer BR, Yeager M, Burdett L, et al. SNP500Cancer: A public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006;34:D617-D621.
28. Chapman JM, Cooper JD, Todd JA, et al. Detecting disease associations due to linkage disequilibrium using haplotype tags: A class of tests and the determinants of statistical power. Hum Hered 2003;56:18-31.
29. Zhang X, Miao X, Guo Y, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006:27:110-117.
30. Bougeard G, Baert-Desurmont S, Tournier I, et al. Impact of the MDM2 SNP309 and TP53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2005;43:531-533.
31. Nelson HH, Wilkojmen M, Marsit CJ, et al. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 2005;26:1770-1773.
32. van Heemst D, Mooijaart SP, Beekman M, et al. Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 2005:40:11-15.
33. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-1169.
34. Lake SL, Lyon H, Tantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003;55:56-65.
35. Wacholder S, Chanock S, Garcia-Closas M, et al. Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-442.
36. Noma C, Miyoshi Y, Taguchi T, et al. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 2004;210: 197-203.
37. Wang Y, Kringen P, Kristensen GB, et al. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 2004:24:21-34.
38. Dumont P, Leu JI, Della PA III, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-365.
39. Chanock S, Wacholder S. One gene and one outcome? No way. Trends Mol Med 2002;8:266-269.
40. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph Consortium. Lancet Oncol 2006;7:27-38.
41. Hytonen AM, Lowhagen O, Arvidsson M, et al. Haplotypes of the interleukin-4 receptor alpha chain gene associate with susceptibility to and severity of atopic asthma. Clin Exp Allergy 2004;34:1570-1575.
42. Kabesch M, Schedel M, Carr D, et al. IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. J Allergy Clin Immunol 2006;117:269-274.
43. Puthothu B, Krueger M, Forster J, et al. Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes. J Infect Dis 2006;193:438-441.